Management
- Which Way Forward?
-
Amidst the constant need to secure steady financing, emerging biotech companies are considering options that will not only produce a larger return, but also increase the likelihood of getting a product to market.
- The New Face of Outsourcing
-
The pressing need to control costs and reduce development timelines has led many biopharmaceutical manufacturers to increasingly outsource components of their clinical research programs.
- Rethinking Informed Consent
-
Cultural understanding, technology and pragmatism are helping create new approaches to clinical research subject enrollment.
- Change is Constant
-
To fully optimize adaptive clinical trial design, the proper technological tools must be in place.
- The Calm Before the Storm
-
A number of fundamental factors could lead to a new and accelerated wave of consolidation in the pharmaceutical and biotech industries.
- Blending with Biotech
-
The strength of the U.K. biotech sector makes it inviting to large pharmaceutical companies looking to expand product portfolios.
- Continuing Ed
-
In the United States, clinical education programs can improve patient compliance and lead to better patient care.
- Pulling the Plug
-
Retiring a failed product is never an easy process, particularly when the withdrawal is for safety reasons. Adhering to a risk management process can help companies keep the damage under control.
- Shock Absorption
-
A comprehensive communications strategy is the key to riding out the bumpy road of biotech.
Web Exclusives
- Turning the Corner
-
After decades of neglect, leading to a rapid increase in incidence, tuberculosis started gaining attention from industrialized nations over the past 10 years. With this new focus, TB’s incidence has started to decrease—but barely.
- A Weighty Problem
-
As pharmaceutical companies search for a blockbuster fat-fighting drug, the biggest battle is against side effects.